Monitoring of Cerebral Blood Flow in Patients on Extracorporeal Membrane Oxygenation
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Mar 21, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how changes in blood flow to the brain occur during a specific treatment called venovenous extracorporeal membrane oxygenation (VV-ECMO). This treatment is used for patients with severe lung problems that don’t respond to other therapies. Researchers want to understand if quickly correcting high levels of carbon dioxide in the blood, which is often a reason for using VV-ECMO, might harm the brain by reducing blood flow. The goal is to measure how blood flow to the brain changes during this treatment.
To participate in this study, individuals must be over 18 years old and have a strong reason to need VV-ECMO, with a special device in place to monitor their blood. However, some individuals may be excluded if their brain blood flow can't be measured, if they have had previous brain surgery, or if they are receiving ECMO treatment at a different hospital. Participants can expect to be closely monitored during their treatment, and their doctors will use this information to better understand the effects of VV-ECMO on brain health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria:
- • High suspicion of an indication for VV-ECMO;
- • Arterial line present to enable blood sampling;
- • Older than 18 years.
- Exclusion Criteria:
- • Subjects will be excluded if the cerebral blood flow cannot be measured using the transcranial Doppler
- • VA-ECMO or ECPR;
- • No possibility for neuromonitoring measurements due to technical difficulties, e.g. post-craniotomy, unsuitable transcranial window;
- • No possibility for neuromonitoring measurements due to circumstantial difficulties, e.g. ECPR;
- • Contraindications for ECMO;
- • ECMO is initiated in another center.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam Zuidoost, , Netherlands
Patients applied
Trial Officials
Alexander Vlaar, MD PhD MBA
Principal Investigator
Department of Intensive Care, Amsterdam UMC, location AMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials